Significant progress has been made in the development of targeted therapy in metastatic clear cell renal cancer (RCC). However we appear to have reached a plateau in terms of survival with the drugs that are currently available. This is most likely due to cross resistance between drugs. Understanding acquired resistance to targeted therapy and the biomarkers associated with it is a major goal for the future.
展开▼
